Here is a thread to explain the findings of this study, that used computational tools to predict T cell reactive sequences in #SARSCOV2 subunit vaccines.

The bottom line: there is no cause for alarm.

Here is why (1/n)
Our adaptive immune system has 2 types of white blood cells known as lymphocytes. T cells and B cells. These lymphocytes give us protection from wide variety of pathogens. Each lymphocyte has unique receptor that detect specific features of a pathogen. (2/n)
B cells detect pathogens structures through antibodies. T cells cannot detect pathogens on their own. They can only “see” pathogen when tiny pieces of viral proteins (peptides) are presented by molecules called major histocompatibility complex (MHC). (3/n)
T cells that detect specific pathogen peptide on MHC become activated and functional. Humans carry multiple copies of MHC genes (thru polymorphism and polygeny). MHC genes are the most diverse set of genes in human genome. (4/n)
Some are called class I MHC, which present peptides to CD8 T cells (killer cells). Others are called class II MHC, which present peptides to CD4 T cells (helper cells).
Why are there so many types of MHC in the human genome? (5/n)
Well, there are infinite possible amino acid sequences that pathogens can have (due to diversity and mutation). Each MHC can only present peptide that contain specific amino acid motifs. If we relied on one MHC to present pathogen peptides,.. (6/n)
..humans will be vulnerable to infection by those pathogens that do not contain such peptide motifs. Frequencies of each type of MHC genes vary widely across the globe. (7/n)
frontiersin.org/articles/10.33…
Back to the study in question. The authors used computational modeling to predict peptides that are likely to be presented to T cells by MHC molecules in White, Black and Asian populations. (8/n)
cell.com/cell-systems/f…
Within just the receptor binding domain (RBD) of the spike protein (221 amino acid), 0.8% of White, and 37.3% of Asian had no predicted peptides that bind to their MHC class II proteins. However Moderna, Pfizer, AstraZeneca vaccines all use the full length S (1273 aa). (9/n)
Good news is that authors found that >99% of White, Black and Asian populations’ MHC class I can present at least 5 peptides from the Spike protein. On MHC class II, >98% of all people have at least 3 peptides predicted to be presented. (10/n)
What does this mean? That current leading vaccine candidates have the capacity to generate good T cell responses in diverse populations. T helper cells will also stimulate good antibody responses from B cells. (11/n)
The ultimate proof of vaccine-induced protection will become available when millions of people get vaccinated. Until then, there is little need to worry about Blacks and Asians not being protected by vaccines. All my figures were made by @BioRender. (End)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Prof. Akiko Iwasaki

Prof. Akiko Iwasaki Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VirusesImmunity

7 Nov
Do some people have cross-reactive antibodies to #SARSCoV2? If so, who are they? And are these cross-reactive Abs protective against #COVID19? A fascinating study by @KevinWNg et al provides answers. Thread. (1/n)

science.sciencemag.org/content/early/…
Do some people have cross-reactive antibodies? The answer is yes. SARS-CoV-2 Spike-reactive IgG was detected in 5 of 34 SARS-CoV-2-uninfected individuals with RT-qPCR-confirmed HCoV infection, as well as in 1 of 31 individuals without recent HCoV infection. (2/n)
Who has cross-reactive anti-spike antibodies? Mostly children and adolescents. The prevalence of SARS-CoV-2 S-reactive IgG antibodies peaked at 62% between 6 and 16 years of age. This age group is also the one in which antibodies to seasonal coronaviruses peak.(3/n)
Read 8 tweets
30 Oct
So happy to see a paper by my graduate student, Daniel Kim, chosen as a spotlight for the @JVirology 👏🏼 Daniel found that HSV-1 genome binds to RUNX1 and represses transcription of viral genes - a possible viral strategy to achieve latent infection. (1/n)

jvi.asm.org/content/94/22/…
Herpesviruses establish latent infection in neurons and leukocytes that express RUNX1 (transcription factor). Curiously, herpesvirus genomes are enriched in RUNX1 binding sites but not other viruses. (2/n)
Overexpression of RUNX1 but not RUNX3 (a related transcription factor that is not expressed in the cell type in which HSV-1 established latency) blunts HSV-1 infection in vitro. (3/n)
Read 5 tweets
25 Oct
As we approach the cold winter months in the Northern Hemisphere, I want to share these movies of mucociliary clearance (MCC) in the trachea of mice housed at 10% vs. 50% relative humidity (RH). Captured by @ericsongg (1/n)

This is MCC at 50% RH 👇🏽
And here is MCC of mice kept at 10% RH 👇🏽

For more, please read our original paper.

pnas.org/content/116/22…
(2/n)
MCC is a key mechanism of removal of inhaled particles, including viruses and bacteria. It is a primary defense mechanism of the respiratory tract. The dry air dehydrates the mucus and periciliary layer, impairing MCC. (3/n)

annualreviews.org/doi/abs/10.114…
Read 4 tweets
16 Oct
In this new Commentary, @SaadOmer3 and I discuss the birth & evolution of vaccine science, how vaccinations have changed our world, the current state of vaccines, remaining challenges & future outlook. #VaccinesSaveLives (1/n)

cell.com/cell/fulltext/…
Live attenuated vaccines worked well by themselves. But, immunization using toxoid alone induced poor immunity. #GastonRamon found that toxoid injected with ‘stuff’ incl. tapioca, lecithin, agar, starch oil, saponin or breadcrumbs improved immunity. (2/n)

tandfonline.com/doi/full/10.10…
While Alum became the adjuvant used in vaccines for past 100 years, there is a recent expansion in new adjuvants with potent capacity to boost immunity to vaccines. Discovery of pattern recognition receptors and their ligands laid foundation for this👇🏽 @YaleIBIO (3/n)
Read 6 tweets
30 Sep
Are you confused about the role of type I interferons (IFN) in #SARS_CoV_2 infection?

Here is my speculation on what makes IFN-I helpful vs. harmful in #COVID19 patients - it comes down to timing and dose. A short thread.

All figures made by @BioRender & @annsea_park (1/n)
In the best case scenario, a rapid and robust induction of IFN-I should result in viral control and mild disease. This may happen in young people, or with low viral exposure settings. For a discussion we wrote, please read this.
(2/n)
cell.com/cell-host-micr…
In older adults or after high dose viral exposure, impaired IFN response early during infection results in enhanced viral replication, and prolonged levels of IFN-I and IFN-III responses that could result in pathological consequences and severe disease. (3/n)
Read 9 tweets
13 Sep
I am the luckiest person in the world to have such wonderful trainees who organized the most amazing #IwasakiLabReunion/birthday zoom party yesterday. I am still in awe of how incredibly inspiring it was. Here are a few highlights I want to share with you. (1/) ImageImage
The event started with a delicious lunch delivered to my door for me and my family, to be followed later by my favorite dinner 🍣and 🎂 🍾 🎁 in the evening 😋 They really know how to spoil me! The entire day was packed with amazing talks, trivia sessions and Prince songs 💜(2/)
So 🙏🏼 to everyone who organized this incredible reunion and thoughtful presents - @maria_tokuyama @MelissaLV14 Kris Sepanek @jofrank1088 @JeffGehlhausen @Myoungjoo @peowenlu @carolilucas @aliceluculligan @tianyangmao @annsea_park @marioph13 @taka_takehiro @YYexin Pat Wong (3/)
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!